A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease

Launched by TARGET PHARMASOLUTIONS, INC. · Aug 11, 2017

Keywords

ClinConnect Summary

The TARGET-IBD study is a 5-year research project looking at patients with Inflammatory Bowel Disease (IBD), which includes conditions like Crohn's disease, ulcerative colitis, and indeterminate colitis. This study aims to gather information about how well current and future treatments for IBD work in real-life settings, both in hospitals and community clinics. It will track the safety and effectiveness of these therapies over time, helping to improve care for people with IBD.

To participate, individuals must be at least 2 years old and have been diagnosed with one of the IBD conditions. They should also be receiving treatment for their condition outside of a clinical trial and plan to continue follow-up visits for their IBD care. Participants will be asked to share their experiences and medical information during the study, which could help doctors understand more about managing IBD in everyday practice. It's important to note that those who are involved in other treatment studies or have had a total removal of the colon for ulcerative colitis are not eligible for this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adults and children (age 2 or older) with a diagnosis of Crohn's disease (CD), Ulcerative colitis (UC), or Indeterminate colitis (IBDU) having been prescribed any IBD treatment (initial or subsequent) outside of a clinical trial.
• • 2. Have plans for future visits at the site for continued management of IBD.
• Exclusion Criteria:
• • 1. Inability to provide written informed consent/assent.
• • 2. Being enrolled in any interventional study or trial for IBD treatment. Note: Patient may be enrolled in other registries or studies where IBD treatment outcomes are observed and/or reported (such as center-based registries).
• • 3. Prior total abdominal colectomy for UC or IBDU.